Abstract: A composition containing an EDTA complex in the form of a suppository is provided. More specifically, the EDTA complex is a magnesium di-potassium EDTA complex. The suppository may contain a controlled release agent which will release the EDTA complex over a period of several hours.
Abstract: The present invention provides orally administered pharmaceutical compositions which contains an effective amount of free base or pharmaceutcially acceptable salts of nalbuphine and/or nalbuphine ester, an oily substance, and a solubility-assisting agent. The oily substance is preferably sesame oil. The solubility-assisting agent is preferably benzyl benzoate. The pharmaceutical composition is useful as an analgesic. The compositions achieves a much higher bioavailability rate and yields much longer lasting effects on nalbuphine than other nalbuphine products currently in the market.
Abstract: The present invention provides compositions and methods for lowering plasma Lp(a) levels in humans. The present invention provides compositions and methods for lowering the risk factors for cardiovascular diseases. Moreover, this invention provides therapeutic alternatives to current pharmaceutical interventions for the lowering of cholesterol, LDL-cholesterol, triglycerides and other metabolic risk factors.
Abstract: The present invention relates to a pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0. Such formulations provide enhanced absorption of morphine or pharmaceutically acceptable salts thereof. In one embodiment, the present invention provides a method for eliciting an analgesic or anesthetic response in a mammal which includes nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.
Type:
Grant
Filed:
June 15, 2000
Date of Patent:
January 13, 2004
Assignee:
Nastech Pharmaceutical Company Inc.
Inventors:
Raja G. Achari, Charanjit R. Behl, Jorge C. deMeireles, Ramneik Dua, Vincent D. Romeo, Anthony P. Sileno
Abstract: Compounds having a structure according to Formula (I):
are effective in a method of increasing erythropoietin and vascularization of tissue in a subject in need thereof.
Type:
Grant
Filed:
April 29, 2002
Date of Patent:
December 9, 2003
Assignee:
The Procter & Gamble Company
Inventors:
Ji-In Kim Almstead, Nicholas John Izzo, David Robert Jones, Richard Masaru Kawamoto
Abstract: The present invention provides compositions and methods for the solubilization of poorly soluble drugs such as triterpenes like betulinic acid and/its derivatives in pharmaceutically acceptable liquid vehicles that avoid use of potentially toxic solvents that are often used for the solubilization of poorly soluble drugs. In the compositions of this invention the drugs remain physically and chemically stable and can be administered intravascularly without undue toxicity from undissolved drug and/or from the solvent vehicles at a drug dose meant to be effective to exhibit clinically significant anticancer activity.
Type:
Grant
Filed:
March 8, 2001
Date of Patent:
December 2, 2003
Assignee:
Dabur Research Foundation
Inventors:
Anand C. Burman, Rama Mukherjee, Honey Bala, Dhiraj Khattar
Abstract: A composition for use as a dental impression material including a polymerizable resin consisting of oligomers or polymers functionalized with groups curable by ring opening metathesis polymerization. These oligomers or polymers are end-capped and/or tethered with said functional groups. The composition also includes a ruthenium carbene complex catalyst, whereby the catalyst initiates ring-opening metathesis polymerization of the composition. The invention includes a paste/paste system in which a base paste includes the polymerizable oligomer or polymer and an inorganic dental filler system and in which a catalyst paste includes the catalyst dissolved in an inert solvent and an inorganic dental filler system.
Abstract: This invention is a method for preventing or treating postoperative ileus comprising administering a vasopressin antagonist such as a compound of Formula (1), where R1, R2, and R3 include hydrogen, halo, alkyl, and alkoxy; R and R5 are hydrogen or alkyl; R4 is hydrogen, phenyl, or substituted phenyl, and pharmaceutically acceptable salts thereof.
Abstract: Treatment with a cyclooxygenase-2 inhibitor and a leukotriene B4 receptor antagonist is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.
Type:
Grant
Filed:
September 12, 2000
Date of Patent:
September 9, 2003
Assignee:
G.D. Searle & Co.
Inventors:
Susan A Gregory, Peter C Isakson, Gary Anderson
Abstract: Retinoid compounds which act specifically or selectively on RAR&agr; receptor subtypes in preference over RAR&bgr; and RAR&Ggr; receptor subtypes, posses desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenecity.
Type:
Grant
Filed:
November 29, 2001
Date of Patent:
August 26, 2003
Assignee:
Allergan, Inc.
Inventors:
Min Teng, Tien T. Duong, Roshantha A. Chandraratna
Abstract: The invention relates to the use of 5HT2A AND 5HT2A/C receptor antagonists for the treatment of snoring and upper airway high resistance syndrome.
Abstract: The compound of the present invention relates to a drug, particularly to a novel isoquinoline derivative or its salt having an If current inhibitory effect without serious side effects such as convulsion and also to a drug, particularly a cardiac rate lowering agent, containing the compound as the active ingredient. Namely, the compound has a current If inhibitory effect and is particularly useful as a cardiac rate lowering agent for preventing ischemic heart diseases such as angina and cardiac infarction and circulatory diseases such as congestive cardiac insufficiency and arrhythmia (supraventricular arrhythmia). The present invention relates to dialkoxy-1,2,3,4-tetrahydroquinoline-2-carbonylpiperidino-3,4-dialkoxypropaneanilide derivatives, etc.
Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.
Type:
Grant
Filed:
May 23, 2000
Date of Patent:
May 13, 2003
Assignee:
Queen's University of Kingston
Inventors:
Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
Abstract: A selective EP2 or EP4 prostanoid receptor agonist can be used to treat female sexual dysfunction. Salts and esters of the agonists can also be used. Formulations comprising such agonists, salts, or esters can be in the form of a cream, gel, ointment, or solid, useful for topical administration.
Abstract: The composition comprises a mixture of olive oil (Olea europea L.) and parsley oil (Petroselinum sativum Hoffm., Petroselinum crispum Mill., Carum petroselinum Benth & Hooker), in a ratio of olive oil: parsley oil, by weight, comprised between 1 and 7. Additionally the composition may contain other vegetable oils, mint oil, menthol and chlorophyll. These compositions may be presented in several forms including sweets, chewing-gum, dentifrice paste, mouthwashes and pharmaceutical compositions, especially as soft gelatine capsules, for which purpose they incorporate the suitable additives, vehicles and excipients for its processing in the desired form of presentation. The composition is suitable for the treatment of halitosis.
Abstract: A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid/arginine) of ⅕ to 20, especially ⅕ to ¼; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage.
Abstract: A composition for relieving a sensation of respiratory discomfort and/or for promoting natural regeneration of mucous membranes of the nasal cavity. The composition contains levomenthol at a concentration between 10 and 250 mg/l, dissolved in an aqueous ionic solution having an osmolarity at least equal to that of an aqueous solution of sodium chloride at 9 g/l. The aqueous ionic solution is pure sea water, diluted sea water, an aqueous sodium chloride solution, an aqueous sodium chloride solution further containing at least one salt found in sea water, or a mixture thereof.
Abstract: Methods and kits for removing, treating or preventing head lice infestations in patients in need of such treatment are disclosed and include topically applying to the lice-infested area an effective amount of a driable pediculostatic agent for a time sufficient to immobilize the lice, drying the agent onto the application site and removing the dried agent, thereby removing the lice and nits.
Abstract: A method of inhibiting complement activation, particularly by a transplanted tissue, in a warm-blooded vertebrate. The method includes administering a therapeutically effective amount of a platelet activity modulator to a warm-blooded vertebrate before, during or after a tissue is transplanted to the warm-blooded vertebrate, whereby complement activation by the transplanted tissue is inhibited. The platelet activity modulator can include a combination of a GPIb modulator and a GPIIb/GPIIIa modulator.
Type:
Grant
Filed:
February 1, 2001
Date of Patent:
March 25, 2003
Assignees:
Vanderbilt University, Beth Israel Deaconess Medical Center
Inventors:
Richard N. Pierson, III, George L. Zorn, III, Todd D. Giorgio, Simon Robson, Agnes M. Azimzadeh